Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia

J. Raal, Frederick; C. Scott, Robert; Somaratne, Ransi; Bridges, Ian; Li, Gang; M. Wasserman, Scott; A. Stein, Evan

doi:10.1161/circulationaha.112.144055

Public

Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia

Published in Circulation • Nov 6, 2012

Authors:

Frederick J. Raal

Robert C. Scott

Ransi Somaratne

Abstract

BACKGROUND: Despite statin treatment, many patients with heterozygous familial hypercholesterolemia do not reach desired low-density lipoprotein cholesterol (LDL-C) targets. AMG 145, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) serine protease, demo...

Subject

Medicine

Familial hypercholesterolemia

PCSK9

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!